



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/634,162	08/05/2003	Michael William Wilson	PC25239A	6343
28880	7590	07/09/2004	EXAMINER	
WARNER-LAMBERT COMPANY			HUANG, EVELYN MEI	
2800 PLYMOUTH RD			ART UNIT	
ANN ARBOR, MI 48105			PAPER NUMBER	
			1625	

DATE MAILED: 07/09/2004

Please find below and/or attached an Office communication concerning this application or proceeding.

Office Action Summary

Application No.

10/634,162

Applicant(s)

WILSON, MICHAEL WILLIAM

Examiner

Evelyn Huang

Art Unit

1625

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) ☒ Responsive to communication(s) filed on 26 May 2004.
- 2a) ☐ This action is **FINAL**. 2b) ☒ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) ☒ Claim(s) 1-12 is/are pending in the application.
- 4a) Of the above claim(s) 8-12 is/are withdrawn from consideration.
- 5) ☐ Claim(s) _____ is/are allowed.
- 6) ☒ Claim(s) 1-4 and 7 is/are rejected.
- 7) ☒ Claim(s) 5 and 6 is/are objected to.
- 8) ☐ Claim(s) _____ are subject to restriction and/or election requirement.

Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on _____ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

- 12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
a) ☐ All b) ☐ Some * c) ☐ None of:
1. ☐ Certified copies of the priority documents have been received.
 2. ☐ Certified copies of the priority documents have been received in Application No. _____.
 3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

- | | |
|---|---|
| 1) <input checked="" type="checkbox"/> Notice of References Cited (PTO-892) | 4) <input type="checkbox"/> Interview Summary (PTO-413)
Paper No(s)/Mail Date. _____ |
| 2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948) | 5) <input type="checkbox"/> Notice of Informal Patent Application (PTO-152) |
| 3) <input checked="" type="checkbox"/> Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08)
Paper No(s)/Mail Date _____ | 6) <input type="checkbox"/> Other: _____ |

DETAILED ACTION

1. Claims 1-12 are pending.

Election/Restrictions

2. In response to the Restriction Requirement, Applicants elect without traverse the invention of Group I, Claims 1-7 in part, drawn to a thienopyridine or thiazolopyridine compound. Applicants also elect the compound described in Claim 6 on page 100, lines 9-10 as the species. Claims of the non-elected Groups II to IV are withdrawn from further consideration as being drawn to the non-elected inventions.

Claim Rejections - 35 USC § 112

3. The following is a quotation of the second paragraph of 35 U.S.C. 112:

The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.

Claims 1-4 are rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.

- a. Claim 1, page 93, second formula on the right column and claim 2, page 97, the last two formulae, the R4 on the pyridine would lead to a charge on the nitrogen. Appropriate action is required.

- b. The substituent R in formulae 2, 4, 6, 8, 9, 12, 13 has no antecedent basis in the base claim 1 wherein only R10 is described in the definitions of X, Y.

- c. It is recommended that 'suitable' be deleted from 'suitable substituents' in claim 1 to better define the claim, as the criteria for suitability have not been described in the specification.

The rejection is applicable to claims dependent on the above claims.

Art Unit: 1625

Claim Rejections - 35 USC § 102

4. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless –


(b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.

5. Claims 1, 2, 4 are rejected under 35 U.S.C. 102(b) as being anticipated by Lee et al. (Journal of Heterocyclic Chemistry (2000), 37: 363-372, PTO-1449). Compounds 5a, 5c (page 366) are encompassed by the instant claims.

6. Claims 1, 2, 4 are rejected under 35 U.S.C. 102(b) as being anticipated by Giles et al. (European Journal of Medicinal Chemistry (1980), 5(6):499-502, PTO-1449). Compound 2(e) (page 502) is encompassed by the instant claims.


7. Claims 1, 4 are rejected under 35 U.S.C. 102(b) as being anticipated by Shen et al. (4038396, PTO-1449). Compounds of Examples 167, 171, 173, 176-182, 184-188 (column 31, Table V) are encompassed by the instant claims.

8. Claims 1, 2, 4 are rejected under 35 U.S.C. 102(b) as being anticipated by Morimoto et al. (5284661). Compound of Example 9 (column 16, Table 1) is encompassed by the instant claims.




9. Claims 1, 2, 4 are rejected under 35 U.S.C. 102(b) as being anticipated by Elliott et al. (6001949). Compound of Example 27 (column 51) is encompassed by the instant claims.

Art Unit: 1625




●2 HCl

10. Claims 1, 2, 4 are rejected under 35 U.S.C. 102(b) as being anticipated by Suzuki et al. (5977132). Compound of the following structure is encompassed by the instant claims.



11. Claims 1, 2, 4 are rejected under 35 U.S.C. 102(b) as being anticipated by Kramberger et al. (Journal of Heterocyclic Chemistry (1975), 12: 337-342). Compound of the following structure is encompassed by the instant claims.



Claim Rejections - 35 USC § 102

12. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless –

(e) the invention was described in (1) an application for patent, published under section 122(b), by another filed in the United States before the invention by the applicant for patent or (2) a patent granted on an application for patent by another filed in the United States before the invention by the applicant for patent, except that an international application filed under the treaty defined in section 351(a) shall have the effects for purposes of this subsection of an application filed in the United States only if the international application designated the United States and was published under Article 21(2) of such treaty in the English language.

Art Unit: 1625

Claims 1-4 are rejected under 35 U.S.C. 102(e) as being anticipated by Bunker (US 2003/0144274).

The applied reference has a common assignee with the instant application. Based upon the earlier effective U.S. filing date of the reference, it constitutes prior art under 35 U.S.C. 102(e). This rejection under 35 U.S.C. 102(e) might be overcome either by a showing under 37 CFR 1.132 that any invention disclosed but not claimed in the reference was derived from the inventor of this application and is thus not the invention "by another," or by an appropriate showing under 37 CFR 1.131.

The species compounds of claim 20 (pages 49-50) are encompassed by the instant claims.

Double Patenting

13. The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the "right to exclude" granted by a patent and to prevent possible harassment by multiple assignees. See *In re Goodman*, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); *In re Longi*, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); *In re Van Ornum*, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); *In re Vogel*, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); and, *In re Thorington*, 418 F.2d 528, 163 USPQ 644 (CCPA 1969).

A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) may be used to overcome an actual or provisional rejection based on a nonstatutory double patenting ground provided the conflicting application or patent is shown to be commonly owned with this application. See 37 CFR 1.130(b).

Effective January 1, 1994, a registered attorney or agent of record may sign a terminal disclaimer. A terminal disclaimer signed by the assignee must fully comply with 37 CFR 3.73(b).

Claims 1-4, 7 are provisionally rejected under the judicially created doctrine of obviousness-type double patenting as being unpatentable over claims 18-20 of copending Application No. 10/264764. Although the conflicting claims are not identical, they are not patentably distinct from each other because the compounds of the copending claims are encompassed by the instant claims.

Art Unit: 1625

This is a provisional obviousness-type double patenting rejection because the conflicting claims have not in fact been patented.

Claim Objections

14. Claims 1-4, 6-7 are objected to because they contain non-elected subject matter.

Amending the claims to the elected subject matter would overcome the objection.

Claim 5 is objected to because it is dependent on the rejected base claim 1.


Conclusion

15. The compounds of claims 5-6 within the elected Group I invention are allowable. These compounds, wherein A is amido, R1 is optionally substituted benzyl or pyridylmethyl and R2 is optionally substituted benzyl, are neither anticipated nor rendered obvious by the prior art of record.

16. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Evelyn Huang whose telephone number is 571-272-0686. The examiner can normally be reached on Tuesday-Friday.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Cecila Tsang can be reached on 571-272-0562. The fax phone number for the organization where this application or proceeding is assigned is 703-872-9306.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).


Evelyn Huang
Primary Examiner
Art Unit 1625